Welcome to our dedicated page for JUPITER NEUROSCIENCES SEC filings (Ticker: JUNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jupiter Neurosciences, Inc. filings document a clinical-stage pharmaceutical issuer with common stock listed on the Nasdaq Capital Market and a business built around the JOTROL™ resveratrol platform and Nugevia™ products. Material-event reports cover standby equity purchase and registration-rights agreements, convertible promissory notes, amendments to installment provisions, and Nasdaq continued-listing notices.
Proxy materials disclose annual meeting matters, board governance and stockholder voting procedures. Rule 12b-25 notices document delayed periodic reports for annual and quarterly filings, while capital-structure disclosures address common stock, potential share issuances and related financing limitations.
Jupiter Neurosciences, Inc. files a prospectus supplement to its Form S-1 prospectus and attaches its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company discloses Nasdaq listing symbol JUNS, a closing share price of $0.3440 on May 7, 2026, and 36,281,252 shares of common stock issued and outstanding as of March 31, 2026. The 10-K describes Jupiter’s clinical-stage platform JOTROL™, its consumer Nugevia product line, an FDA-cleared IND for a Phase IIa Parkinson’s study (final IND approval in November 2025) expected to begin dosing in Q2 2026 with initial results anticipated about 12 months after first dosing. The 10-K highlights substantial financing needs, auditor explanatory going-concern language, patent coverage through 2036, Asian business-development agreements, and material risk factors affecting operations and liquidity.
Jupiter Neurosciences, Inc. filed a shelf registration on Form S-3 to offer, from time to time, up to $100,000,000 of common stock, preferred stock, debt securities, warrants, rights and/or units. The shelf permits multiple offerings under prospectus supplements describing specific terms and sale methods.
The company reported 36,281,252 shares of common stock issued and outstanding as of March 31, 2026, a public float of $13,632,945 based on 22,608,533 non-affiliate shares at $0.603 per share as of February 15, 2026, and a last reported sale price of $0.3940 on April 14, 2026. The prospectus states net proceeds will be used for general corporate purposes, including clinical trials and R&D.
Jupiter Neurosciences, Inc. files its annual report describing a clinical-stage CNS drug pipeline built around its proprietary resveratrol formulation JOTROL™ and a new consumer wellness brand, Nugevia. The company is advancing a Phase IIa Parkinson’s trial and planning additional studies in mild cognitive impairment, Alzheimer’s disease and rare disorders such as MPS I and MELAS.
Jupiter raised $11 million in December 2024 via a Nasdaq-listed public offering and is pursuing Asian partnerships and out-licensing to support development. However, it has generated minimal product revenue to date, carries indebtedness, requires substantial additional capital, and discloses that management and auditors see substantial doubt about its ability to continue as a going concern.
Jupiter Neurosciences, Inc. reported that Nasdaq has notified the company it is out of compliance with two continued listing standards for the Nasdaq Capital Market. The company’s common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days through February 25, 2026, and its market value of listed securities was below the required $35 million for the 30 consecutive business days ended February 26, 2026.
The company has until August 25, 2026 to regain compliance with each requirement, generally by maintaining a bid price of at least $1.00 and a market value of listed securities of at least $35 million for a minimum of 10 consecutive business days. If it fails to do so, its common stock may be subject to delisting, though the company could seek additional time or appeal. The company is monitoring its stock price and market value and may consider actions such as a reverse stock split.
Jupiter Neurosciences, Inc. updated the terms of its financing arrangement with YA II PN, Ltd. (Yorkville) tied to earlier advances of up to $6.0 million under convertible promissory notes. These notes were issued in connection with a Standby Equity Purchase Agreement and later amended.
On February 20, 2026, the company and Yorkville signed an Omnibus Amendment that changes the “Monthly Payments” section of the amended and restated convertible notes. The start of monthly installments is pushed to April 1, 2026, the payment amounts follow a variable schedule, and provisions on Advance Notices are revised.
Jupiter Neurosciences can continue to choose whether to make installment payments in cash, through Advance Repayment under the notes, or by combining both methods. The filing also records this arrangement as a direct financial obligation for the company.
Jupiter Neurosciences, Inc. amended its disclosure of a standby equity and note financing with Yorkville. The company corrected its reported common shares outstanding as of October 24, 2025 to 34,294,446 and lowered the Nasdaq Exchange Cap on shares issuable to Yorkville from 7,180,504 to 6,855,459 shares, which equals 19.99% of pre-deal shares.
Under the Standby Equity Purchase Agreement, Jupiter may sell up to $20.0 million of common stock to Yorkville at its discretion, priced at 97% of the lowest daily VWAP over a three-day period for each advance. Yorkville also provided up to $6.0 million in prepaid advances via two convertible notes bearing 8% interest, issued at a 7% discount and initially convertible at $1.50 per share. Until the notes are fully repaid, all advance proceeds under the equity line must first repay the notes.
Jupiter Neurosciences (JUNS) filed its Q3 2025 report, highlighting higher operating spend, a wider loss, and a going‑concern warning. For the quarter ended September 30, 2025, the company posted a net loss of $2,288,034 as research and development rose to $816,697 and general and administrative expenses increased to $1,480,356. For the nine months, net loss was $6,069,866.
Cash was $723,797 as of September 30, 2025, and operating cash outflows totaled $3,045,713 year‑to‑date. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern.
Subsequent to quarter‑end, the company entered a Standby Equity Purchase Agreement for up to $20.0 million and received a $3,720,000 pre‑paid advance via an 8% note convertible at $1.50 per share, subject to a 4.99% beneficial‑ownership cap and a Nasdaq 19.99% exchange cap of 7,180,504 shares unless stockholder approval is obtained. Shares outstanding were 34,294,546 as of September 30, 2025; as of November 14, 2025, 34,426,355 shares were outstanding.